Main Article Content
Introduction: Abnormal uterine bleeding is a significant debilitating clinical condition and effect 14-25% of women. We sought to determine the effectiveness and potency of Ormeloxifene in the treatment of AUB-O in this longitudinal investigation.
Objectives: To study the efficacy and acceptability of Ormeloxifene in management of AUB.
Methodology: The study was conducted in Department of Obstetrics and Gynecology of BLDE(DU) Shri B M Patil medical college. In this study 52 patients aged 30-55 years, presenting with heavy menstrual bleeding were enrolled. Patients with any structural pelvic cause, liver dysfunctions, who are using IUCDs or oral contraceptives, were excluded from the study. All the participants were subjected for complete menstrual history, medical history, clinical examination and laboratory evaluation done. All cases received Ormeloxifene 60mg twice weekly for the first 12 weeks, followed by once weekly for next 12 weeks. The participants were followed every three months and six months for subjective and objective improvement in menstrual blood loss by history, measuring PBAC score, endometrial thickness, hemoglobin concentration.
Results: 50 out of 52 study participants completed the treatment and all 50 had improvement in symptoms of HMBL after using Ormeloxifene for 6 months. They had minimal and minor side effects. There was improvement in hemoglobin concentration, PBAC score, TVS-ET score in all the participants.
Conclusion: Ormeloxifene is effective and safe in patients with AUB-O and this can reduce the burden of surgery in patients suffering from AUB-O.
Munro MG, Critchley HOD, Fraser IS., FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018 Dec;143(3): 393-408.
Singh HO, Singh A, Dhole TN, Nain S. Effect of ormeloxifene for management of dysfunctional uterine bleeding. Biochem Physiol 2015;4:174.
Fraser IS, Sungurtekin U. Defining menstrual disturbances. In: MacLean A, O’Brien PM, editors. Study Group on Menstrual Disorders. London: Royal College of Obstetricians and Gynaecologists; 2000. p. 141 52.
Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: An update on recent clinical findings. Obstet Gynecol Surv 2008;63:163 81
Dhananjay BS, Sunil Kumar N. The Role of Sevista in the Management of Dysfunctional Uterine Bleeding. J Clin Diagnostic Res. 2013;7(1):132134.
Makker A, Tandon I, Goel MM, Singh M, Singh MM. Effect of ormeloxifene, a selective estrogen receptor modulator, on biomarkers of endometrial receptivity and pinopode development and its relation to fertility and infertility in Indian subjects. Fertility and sterility. 2009 Jun 1;91(6):2298-307
Agarwal N, Singh S, The efficacy and safety of Ormeloxifene in Dysfunctional Uterine Bleeding. IOSR-JPBS. 2013; 5(5): 18-21.
Nandhini G. M., Hiremath P. B., Shameera Banu A A study of efficacy of ormeloxifene in abnormal uterine bleeding of ovulatory disorders. Int J Reprod Contracept Obstet Gynecol. 2022 Apr;11(4):1230-1235
Dhananjay BS, Nanda SK. The role of sevista in the management of dysfunctional uterine bleeding. Journal of clinical and diagnostic research: JCDR. 2013 Jan;7(1):132.